Advertisement

Tumor Biology

, Volume 35, Issue 10, pp 9957–9966 | Cite as

Silencing survivin activates autophagy as an alternative survival pathway in HCC cells

  • Yu-Jia Chang
  • Li-Tzu Li
  • Hsin-An Chen
  • Chin-Sheng Hung
  • Po-Li Wei
Research Article

Abstract

Autophagy is a survival mechanism that is activated in response to nutrient deprivation. The link between aberrant autophagy and cancer has been increasingly recognized. Survivin, an anti-apoptotic molecule, and the autophagy pathway are correlated with therapeutic responses to cancer. However, the role of autophagy in cancer progression remains unclear. Here, we generated survivin knockdown cells (survivin-KD) by introducing a short interfering RNA (siRNA) into hepatocellular carcinoma (HCC) cells, and we observed a 20 % reduction in the survival of these survivin-KD cells, as determined by MTT assay. In addition, an increased number of stress granules, increased positive staining by acridine orange and a shift in the high side scatter (SSC) cell population in flow cytometry analysis were observed in survivin-KD cells. Furthermore, electron microscopy revealed an increased number of autophagosomes in survivin-KD cells compared with scrambled control cells. Finally, we treated cells with an autophagy inhibitor, 3-MA, and observed a decrease in cell survival in survivin-KD cells compared with scrambled control cells. Our study suggests that an autophagy signal may be activated after the anti-apoptotic molecule survivin is suppressed. This finding implies that autophagy may be an alternative survival pathway in HCC cells and may provide a basis for the development of new therapeutic strategies for HCC.

Keywords

Survivin Autophagy HCC Anti-proliferation 

Abbreviations

HCC

Hepatocellular carcinoma

Notes

Acknowledgments

This study was supported by grants from Taipei Medical University and Shuang Ho Hospital (101TMU-SHH-9) and Ministry of Science and Technology (NSC-101-2314-B-038-016-MY3 and NSC-101-2314-B-038-029-MY3).

Conflicts of interest

None.

References

  1. 1.
    LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17:3247–59.CrossRefPubMedGoogle Scholar
  2. 2.
    Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis. 2007;28:1133–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Johnson ME, Howerth EW. Survivin: a bifunctional inhibitor of apoptosis protein. Vet Pathol. 2004;41:599–607.CrossRefPubMedGoogle Scholar
  4. 4.
    Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002;59:1406–12.CrossRefPubMedGoogle Scholar
  5. 5.
    Giodini A, Kallio MJ, Wall NR, Gorbsky GJ, Tognin S, Marchisio PC, et al. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002;62:2462–7.PubMedGoogle Scholar
  6. 6.
    Zhang M, Mukherjee N, Bermudez RS, Latham DE, Delaney MA, Zietman AL, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005;64:293–302.CrossRefPubMedGoogle Scholar
  7. 7.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.CrossRefPubMedGoogle Scholar
  8. 8.
    A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: The cancer of the liver italian program (clip) investigators. Hepatology. 1998;28:751–5.Google Scholar
  9. 9.
    Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL. Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials. 2010;31:55–61.CrossRefPubMedGoogle Scholar
  10. 10.
    Sugioka A, Tsuzuki T, Kanai T. Postresection prognosis of patients with hepatocellular carcinoma. Surgery. 1993;113:612–8.PubMedGoogle Scholar
  11. 11.
    Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Liver cancer study group of Japan. Ann Surg. 1990;211:277–87.Google Scholar
  12. 12.
    Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA. Primary hepatic malignancy: surgical management and determinants of survival. Surgery. 1989;106:740–8. discussion 748–749.PubMedGoogle Scholar
  13. 13.
    Paquet KJ, Koussouris P, Mercado MA, Kalk JF, Muting D, Rambach W. Limited hepatic resection for selected cirrhotic patients with hepatocellular or cholangiocellular carcinoma: a prospective study. Br J Surg. 1991;78:459–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Hu H, Li Z, Chen J, Wang D, Ma J, Wang W, et al. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating akt/survivin signalling in hepatocellular carcinoma cells. Gut. 2011;60:710–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Mizushima N, Levine B. Autophagy in mammalian development and differentiation. Nat Cell Biol. 2010;12:823–30.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, et al. Survivin-mediated cancer cell migration through grp78 and epithelial-mesenchymal transition (emt) marker expression in mahlavu cells. Ann Surg Oncol. 2012;19:336–43.CrossRefPubMedGoogle Scholar
  18. 18.
    Hung CS, Lin SF, Liu HH, Kuo LJ, Li LT, Su HY, et al. Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:2744–52.CrossRefPubMedGoogle Scholar
  19. 19.
    Hung CS, Liu HH, Huang MT, Cheng CW, Kuo LJ, Ho YS, et al. Knockdown survivin expression reduces the efficacy of curcumin treatment in hepatocellular carcinoma cells. Ann Surg Oncol. 2012;19:3547–55.CrossRefPubMedGoogle Scholar
  20. 20.
    Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on hiv-1: interaction of oligomannose dendrons with human monoclonal antibody 2g12 and dc-sign. Proc Natl Acad Sci U S A. 2008;105:3690–5.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, Kohler K, et al. Membrane nanotubes physically connect t cells over long distances presenting a novel route for hiv-1 transmission. Nat Cell Biol. 2008;10:211–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (grp78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:1703–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Chiu HW, Lin JH, Chen YA, Ho SY, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances cell-killing effects in human fibrosarcoma cells in vitro and in vivo through induction of both autophagy and apoptosis. Autophagy. 2010;6:353–65.CrossRefPubMedGoogle Scholar
  25. 25.
    Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63:2103–8.PubMedGoogle Scholar
  26. 26.
    Traganos F, Darzynkiewicz Z. Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol. 1994;41:185–94.CrossRefPubMedGoogle Scholar
  27. 27.
    Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014;15:2494–516.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Han L, Tang C, Yin C. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials. 2014;35:4589–600.CrossRefPubMedGoogle Scholar
  29. 29.
    Necochea-Campion R, Chen CS, Mirshahidi S, Howard FD, Wall NR. Clinico-pathologic relevance of survivin splice variant expression in cancer. Cancer Lett. 2013;339:167–74.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Wang Q, Chen Z, Diao X, Huang S. Induction of autophagy-dependent apoptosis by the survivin suppressant ym155 in prostate cancer cells. Cancer Lett. 2011;302:29–36.CrossRefPubMedGoogle Scholar
  31. 31.
    Ulasov IV, Tyler MA, Zhu ZB, Han Y, He TC, Lesniak MS. Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol. 2009;34:729–42.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Kang R, Zeh HJ, Lotze MT, Tang D. The beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011;18:571–80.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Niu TK, Cheng Y, Ren X, Yang JM. Interaction of beclin 1 with survivin regulates sensitivity of human glioma cells to trail-induced apoptosis. FEBS Lett. 2010;584:3519–24.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hou MF, Kuo HC, Li JH, Wang YS, Chang CC, Chen KC, et al. Orai1/cracm1 overexpression suppresses cell proliferation via attenuation of the store-operated calcium influx-mediated signalling pathway in a549 lung cancer cells. Biochim Biophys Acta. 1810;2011:1278–84.Google Scholar
  35. 35.
    Wang JY, Chen BK, Wang YS, Tsai YT, Chen WC, Chang WC, et al. Involvement of store-operated calcium signaling in EGF-mediated cox-2 gene activation in cancer cells. Cell Signal. 2012;24:162–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Chang WC, Woon PY, Hsu YW, Yang S, Chiu YC, Hou MF. The association between single-nucleotide polymorphisms of orai1 gene and breast cancer in a Taiwanese population. Sci World J. 2012;2012:916587.Google Scholar
  37. 37.
    Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009;15:124–34.CrossRefPubMedGoogle Scholar
  38. 38.
    Huang WC, Chai CY, Chen WC, Hou MF, Wang YS, Chiu YC, et al. Histamine regulates cyclooxygenase 2 gene activation through orai1-mediated NFkappaB activation in lung cancer cells. Cell Calcium. 2011;50:27–35.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yu-Jia Chang
    • 1
    • 2
    • 3
    • 4
    • 5
  • Li-Tzu Li
    • 6
  • Hsin-An Chen
    • 7
  • Chin-Sheng Hung
    • 2
    • 3
    • 4
    • 5
  • Po-Li Wei
    • 2
    • 3
    • 4
    • 5
    • 8
  1. 1.Graduate Institute of Clinical Medicine, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  2. 2.Department of Surgery, School of Medicine, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  3. 3.Division of General Surgery, Department of Surgery, Taipei Medical University HospitalTaipei Medical UniversityTaipeiTaiwan
  4. 4.Cancer Center, Taipei Medical University HospitalTaipei Medical UniversityTaipeiTaiwan
  5. 5.Taipei Medical UniversityTaipeiTaiwan
  6. 6.Institute of Stem Cell and Translational Cancer ResearchChang Gung Memorial HospitalLinkouTaiwan
  7. 7.Division of General Surgery, Department of Surgery, Shuang Ho HospitalTaipei Medical UniversityTaipeiTaiwan
  8. 8.Taipei CityTaiwan

Personalised recommendations